Page 94 - Mesenchymal Stem cells, Exosomes and vitamins in the fight aginst COVID
P. 94
Intravascular Mesenchymal Stem Cells to Treat Organ Failure and Possible Application in COVID-19
Decrease in hepatic encephalopathy and bacterial peritonitis. No change in esophageal bleeding. Improvement in PLT improved for 1 year. CD8 decreased up to 6 months. IL-10 decreased for 3 months. The frequency of hospitalization decreased because of improved ascites, hypoproteinemia, and quality of life. Bilirubin and ALT interestingly were decreased at 24 weeks. in the third month. In patients with nonresponder hepatitis C, HCV RNA Histo
Findings ALB, preALB, and TB after 1 year but not 2 years. PT and PT activity improved up to 6 months and fibrinogen levels improved for 1 year. HGB improved for 6 months and Improvements in the PBS 40 score, AST, serum IgM at 12 months. ALT, GGT, DBIL improvement at 6 months . No change in TBIL or ALP. CD4 T cells increased and increased for 24 weeks. PTT was decreased up to 24 weeks but no change in PT. MELD No change in MELD scores were obser
Condition Cirrhosis PBC ESLD Cirrhosis Acute on chronic liver failure Cirrhosis
Follow-Up (months) 24 12 6 6 24 12
Result Yes Yes Yes No Yes Yes
Delivery Method HAI IV HAI IV HAI HAI
Type of Stem Cell BM MNC BM MSC (Pas 3–5) WJ MSC (Pas 3) BM MSC (Pas 2) WJ MSC (Pas 3–4) BM MSC (Pas 4–5)
Number of SC Not reported 0.3–0.5 million 30 million 1 million/ kg 100 million (Pas 3–4) 50 million
BMA (mL) 80–100 20 NA 20–40 NA 10–20
Table 3 con't. MSC therapy studies treating liver failure.
No. of Patients in Treatment Group 32 10 50 12 11 18, 19
Type of Study PCT Case series Case series Case series PCT RCT
Year 2014 2014 2015 2015 2016 2016
Author Bai et al, World J Gastroenterol 2014; 20:8660-8666 Wang et al, Stem Cells and Dev 2014; 23:2482-2489 Xue et al, Transplant Proc 2015; 47:412-418 Kantarcıoğlu et al, Turk J Gastroenterol 2015; 26:244-250 Li et al, Stem Cell Rev Rep 2016; 12:645- Suk et al, Hepatology 2016; 64:2185-2197
www.painphysicianjournal.com S411
